The therapeutic activity of Trastuzumab-Qtag2-DM1 and Trastuzumab-Qtag2-MMAE was followed in HER2/neu overexpressing breast cancer mouse xenograft model and compared to commercially available T-DM1. Here, ERBB2 is linked to breast carcinoma.